USP22 and melanoma: A recent study demonstrated that ubiquitin-specific peptidase 22 (USP22) interacted with and stabilized YAP, which in turn conferred resistance to the BRAF inhibitor vemurafenib and provided new therapeutic avenues to target USP22/YAP as an option for melanoma treatment [224].